Call for Abstract
International Conference on Molecular Markers and Cancer Therapeutics, will be organized around the theme “Clinical Advancements in Discovery of Molecular Markers in Cancer Treatment”
Molecular Markers 2018 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Molecular Markers 2018
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
A molecular marker is a DNA arrangement in the genome which can be found and recognized. DNA, for instance, is a molecular marker containing information about hereditary disorders, family history and the transformative history of life. Genetic markers are utilized to analyze the autosomal recessive hereditary disorder cystic fibrosis, phylogenetic and DNA Barcoding. Further, living things are known to shed one of the kind chemicals, including DNA, into the environment as proof of their essence in a specific area. Other organic markers, similar to proteins, are utilized as a part of symptomatic tests for complex neurodegenerative disorders.
- Track 1-1Nucleic acid-based biomarkers
- Track 1-2Protein biomarkers
- Track 1-3Small molecule biomarkers
- Track 1-4Lipid biomarkers
- Track 1-5Micro RNA biomarkers
- Track 1-6Genomic biomarker
- Track 1-7Transcriptomic biomarker
- Track 1-8Metabolomics biomarker
- Track 1-9Drug activity markers
- Track 1-10Proteomic biomarker
- Track 1-11Cancer markers
The achievements in the utilization of immunotherapy to treat disease have prompted a multiplicity of new compounds being developed. Novel clinical-grade biomarkers are expected to direct the decision of these specialists to acquire the maximal probability of patient advantage. Predictive biomarkers for immunotherapy vary from the traditional biomarkers utilized for focused treatments: the unpredictability of the insusceptible response and tumor biology requires a more comprehensive approach than the utilization of a single analyte biomarker. The circumstance for immuno-oncology (IO) drugs that follow up on the host immune system is that it constitutes the "treatment" for fighting the tumor. The objective of disease immunotherapy is to initiate or reiterate a self-maintaining cycle of tumor immunity empowering it to enhance and engender an anticancer response. In this way, there is a requirement for biomarkers to distinguish the detours and the underlying biology at the individual patient level to manage a suitable therapeutic intervention.
- Track 2-1Liquid biopsy for immuno-oncology
- Track 2-2Tumor neoantigens as biomarker and target identification
- Track 2-3Biomarkers for combinational immunotherapies
- Track 2-4Biomarkers for precision immune-oncology
- Track 2-5Biomarkers in Immune monitoring
- Track 2-6Mutation examination utilizing biomarkers to direct treatments
- Track 2-7Cell multiplication Biomarkers
The major aim of biomarker research in neurology has been to provide clinicians with biochemical and neuroimaging tools that enable accurate diagnosis before widespread neuronal death has occurred. Such biomarkers are a prerequisite for effective secondary prevention strategies, and may also facilitate therapeutics by (i) providing measures of desired biochemical effects of a compound in the preclinical drug discovery phase; (ii) allowing the specific inclusion of early cases that are very likely to develop the disease of interest; and (iii) identifying subgroups of patients according to biochemical patterns to individualize treatment. In addition, biomarker changes during disease progression and correlations between different biomarkers may provide clues on pathogenic mechanisms. Several studies have already been conducted, most of them using the Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers total and phosphorylated tau proteins that reflect the axonal component of the disease and the 42-amino acid fragment of amyloid β (Aβ42) that reflects plaque pathology in the brain to diagnose AD before onset of dementia.
- Track 3-1Early identification of Neurological disorders
- Track 3-2Monitoring of treatment efficiency & progression
- Track 3-3High-performance plasma amyloid-β biomarkers in Alzheimer’s disease
- Track 3-4Biomarkers for α-synuclein pathology associated with Parkinson’s disease (PD)
- Track 3-5Biomarkers for dementia with Lewy bodies (DLB), and multiple system atrophy (MSA)
Clinicians have utilized additional tools to help clinical evaluation and to upgrade their capacity to distinguish the "vulnerable" patient in danger for CVD wherein biomarkers are one such tool to better recognize high-risk people, to analyze ailment conditions expeditiously and precisely, and to viably forecast and treat patients with the disease. In a patient presenting to the emergency department with an acute coronary syndrome, a biomarker may differentiate patients with an acute myocardial infarction (MI) from those with unstable angina, acute pulmonary embolism or an aortic dissection in an opportune manner to encourage targeted management.
- Track 4-1Biomarkers for Heart Failure & Acute Coronary Syndrome
- Track 4-2Biomarkers for Metabolic Syndrome & Cardiovascular Risk
- Track 4-3To assess the likelihood of a therapeutic response
- Track 4-4Determination of the extent of myocardial damage
- Track 4-5Determination of the risk of future recurrences and progression to heart failure
Translational Medicine utilizes a patient-driven way to deal with drug development and is a consequence of the practical application of the changes made in biomarker revelation in the era of personalized medicine(PM). Basic to the translational medicine is the transformation of insights of knowledge from pre-clinical research into early clinical trials. Likewise, TM fosters progressing assessment of clinical biomarker data to both illuminate the following phase of trials and to give feedback into extra pre-clinical trials. Since pre-clinical models are known to be defective at anticipating the human response, the translational medicine groups must utilize biomarkers to quantify however much data as they can in the clinic. This interpretation of learning between pre-clinical and clinical research is important to outline and run successful clinical trials and ultimately deliver effective medicines to patients.
- Track 5-1Novel biomarkers discovery
- Track 5-2Clinical and logical biomarker validation
- Track 5-3Role of biomarkers in clinical decision making
- Track 5-4Biomarkers in Clinical Trials: Design, methodologies and application case trials
- Track 5-5Application of biomarkers in drug discovery and advancement
- Track 5-6Circulating Tumour DNA cells as biomarkers: Case studies for different cancers
Biomarkers are of progressively high significance in medicine, especially in the domain of 'personalized medicine'. They are profitable for predicting prognosis and dosage determination. Besides, they might be useful in recognizing therapeutic and adverse responses and in understanding stratification in light of adequacy or safety prediction. Despite the fact that utilization of the term personalized medicine is regularly constrained to the recognizable proof of the optimal drug and the optimal dose for a subgroup of patients, current personalized medicine applications are significantly more expansive, and might incorporate circumstances of withholding treatment, preventive interventions, or focused on treatment alternatives for individual patients. .
- Track 6-1Anti-inflammatory therapies are effective in inflammatory diseases, such as Crohn’s disease
- Track 6-2For the treatment of melanoma and HIV infection
- Track 6-3PM plays an increasing role in skin cancer therapy
In cell biology, a biomarker is a molecule that permits the detection and isolation of a specific cell type. In genetics, a biomarker is a DNA sequence that causes disease or is related to susceptibility to the ailments. They can be utilized to make hereditary maps of whatever creature is being examined. Cell biomarkers enable cells to be separated, arranged, measured and portrayed by their morphology and physiology. Cell biomarkers are utilized as a part of both clinical and laboratory settings and can segregate between substantial samples of cells based on their antigens. An example of a cell biomarker sorting technique is Fluorescent-activated cell sorting.
- Track 7-1Structural changes of the lysosomal and peroxisomal frameworks - for use as early cell biomarkers
- Track 7-2Cellular biomarkers in the field of ecotoxicology
- Track 7-3Biomarker sorting method - Fluorescent-activated cell sorting
Biomarkers in medicine have increased thorough logical and clinical intrigue. Biomarker characterized as the modification in the constituents of tissues or body fluids give an effective way to deal with understanding the range of chronic illness with application in no less than 5 areas like screening, diagnosis, prognostication, prediction of illness recurrence and restorative monitoring. In this way, biomarkers are biological markers of diseases that can be estimated either in vivo by biomedical imaging or in vitro by laboratory techniques. In medicine, a biomarker can be a traceable substance that is brought into a living being as a way to look at organ function or different aspects of wellbeing.
- Track 8-1Rubidium chloride - radioactive isotope to assess perfusion of the heart muscle.
- Track 8-2Biomarkers in view of measures of the Electroencephalography
- Track 8-3In saliva testing of normal metabolites
Molecular mapping helps in identifying the location of specific markers inside the genome. There are two kinds of maps. To start with is a physical map, which identifies the chromosome and area on it. Furthermore, there is a linkage map recognizes how specific genes are connected to different genes on a chromosome. In some organisms, maps appeared to be "full" of loci of known phenotypic impact and estimations demonstrated that the chromosomal intervals between genes needed to contain DNA. These gaps couldn't be mapped by linkage analysis, on the grounds that there were no markers in those regions. A molecular marker is a site of heterozygosity for some sort of DNA variety. Such a "DNA locus," when heterozygous, can be utilized as a part of mapping analysis.
- Track 9-1Mapping depends on the recombination frequency between molecular markers
- Track 9-2Use of restriction fragment length polymorphisms in mapping
- Track 9-3Use of polymorphism of VNTRs in mapping
Biochemical markers recognize variety at the gene level. Biochemical markers are for the most part the protein marker. These depend on the variation in the grouping of amino acids in a protein molecule. The essential protein marker is alloenzyme. Alloenzymes are various types of an enzyme that are coded by various alleles at a similar locus and these alloenzymes vary from species to species.
- Track 10-1Linkage mapping
- Track 10-2Population examines
- Track 10-3Analysis and administration of Acute Coronary Syndrome (ACS)
- Track 10-4Detection of myocardial corruption
- Track 10-5Biochemical markers for nutritional support
- Track 10-6Utilization of biochemical markers of bone turnover in osteoporosis
The advancements, for example, mass spectrometry, protein and DNA clusters, joined with our comprehension of the human genome, have prompted recharged enthusiasm for the revelation of novel disease biomarkers. Each time of biomarker disclosure is by all accounts related intimately with the development of another and capable scientific innovation. The previous decade has seen an amazing development in the field of extensive scale and high-throughput science, which has added to a period of new innovation improvement. The consummation of various genome-sequencing ventures, the disclosure of oncogenes and tumour-silencer qualities, and on-going advances in genomic and proteomic innovations, together with intense bioinformatics instruments, will have an immediate and significant effect in transit the scan for disease biomarkers .Tumour biomarker disclosure and improvement falls into five applied stages: preclinical exploratory investigations; clinical test and approval; review longitudinal examinations; imminent screening; and randomized control trials. Prostate-particular antigen (PSA [KLK3]), outstanding amongst other biomarkers discovered.
- Track 11-1Auto antibodies
- Track 11-2Lipidomics
- Track 11-3Protein arrays
- Track 11-4Cancer-biomarker-family approach
- Track 11-5Gene profiling
Cancer is the uncontrolled development of unusual cells anywhere in a body. The DNA inside a cell is bundled into endless characteristics, every one of which contains an arrangement of principles urging the cell what capacities to perform, and besides how to create and disengage. A family history of specific cancer can be an indication of a possible procured warning.
The Cancer Diagnostics Market consolidates various parts of treatment and is partitioned on basis of Technology, Application, and Region. Oncology depends upon logical instruments like biopsy or ejection of bits of the growing tissue and analyzing it under the magnifying lens. Other symptomatic devices include endoscopy for the gastrointestinal tract, imaging concentrates like X-bars, CT analyzing, MRI checking, ultrasound and other radiological methodologies, Scintigraphy, Single Photon Emission Computed Tomography, Positron Emission Tomography and nuclear medicine so on.
- Track 12-1Biopsy
- Track 12-2Endoscopy
- Track 12-3CT examination
- Track 12-4MRI examination
Cancer biomarkers are the quantifiable molecular changes to either cancerous or normal tissues of patients. A reliable biomarker can be utilized for cancer analysis, hazard and prognosis evaluations, and for the observation of treatment effectiveness. One of the cancer biomarkers is the Warburg effect which is the shift of mitochondrial vitality generation to a glycolysis dependent metabolism that gives vitality to cells as well as produces moderate building materials for cancer cells to develop.
Cancer Therapeutics exploits the vulnerabilities of disease cells by finding novel and creative small-molecule drugs for the customized treatment of cancer. It likewise creates biomarkers to affirm the adequacy of molecularly focused on treatments. The need of Cancer Therapeutics is to handle the challenge of tumor heterogeneity, malignancy advancement and resistance to drug treatments.
- Uses of Biomarkers in cancer medicine
- Risk assessment
- Prognosis and treatment predictions
- Pharmacodynamics and pharmacokinetic
- Monitoring treatment response
- Uses of biomarkers in cancer research
- Developing drug targets
- Surrogate endpoints
- Experimental Cancer Therapeutics
- Identification of molecular targets for cancer therapy
- Molecular targets for cancer chemoprevention
- Cancer Chemistry and Drug Discovery
- Track 13-1Biomarkers in cancer diagnosis, risk assessment, prognosis and treatment predictions
- Track 13-2Pharmacodynamics and pharmacokinetics
- Track 13-3 Biomarkers in monitoring treatment response
- Track 13-4Biomarkers in cancer research: Developing drug targets and surrogate endpoints
- Track 13-5Experimental cancer therapeutics
- Track 13-6Identification of molecular targets for cancer therapy
- Track 13-7Molecular targets for cancer chemo prevention
- Track 13-8Cancer chemistry and drug discovery
Imaging biomarkers (IBs) are fundamental to the normal administration of patients with cancer. A quantitative imaging biomarker (QIB) is a target characteristic got from an in vivo image estimated on a proportion or interval scale as markers of typical organic procedures, pathogenic procedures or a reaction to a therapeutic intervention. The benefit of QIB's over subjective imaging biomarkers is that they are more qualified to be utilized for follow-up of patients or in clinical trials. Other CT, MRI, PET, and ultrasonography biomarkers are used extensively in cancer research and drug development. Imaging biomarkers have the stand-out favorable position that they examine the right disease focus, for instance, an infarct or tumor. Furthermore, they are non-invasive and allow follow-up especially where imaging modalities without ionizing radiation are used.
- Track 14-1Diagnostic/prognostic biomarkers
- Track 14-2Monitoring biomarkers
- Track 14-3Predictive biomarkers
- Track 14-4Response biomarkers
Next-generation sequencing (NGS) is starting to give effective experiences into genetic mutations and molecular networks are hidden ailment for a wide set of genes. NGS advances guarantee to change various areas in clinical practice, including the approval and examination of sequencing-based biomarkers, a tool progressively pertinent for diagnosis in different disease areas and for the determination and checking of therapeutic treatments. An entire clinical viewpoint keeps on depending on different sorts of testing, in light of imaging or on the investigation of molecular biomarkers. Be that as it may, in this is an extra quality of NGS platforms, which offer versatility to look at various cell properties beyond the determination of genomic sequence alone. The scope of extra applications is exceptionally wide, including transcriptomic profiling, examination of alternative spliced forms and profiling of small RNA populations.
- Track 15-1NGS for the disclosure of biomarkers
- Track 15-2MicroRNA sequencing for the forecast of sicknesses
- Track 15-3SNP as biomarkers
- Track 15-4Cytogenetic and oxidative stress biomarkers
- Track 15-5Genetic-based biomarkers and NGS in customized care of Cancer